OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate Cancer

February 20th 2020

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

February 20th 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.

Dr. Eng on Increasing Awareness for Adolescents/Young Adults With CRC

February 20th 2020

Cathy Eng, MD, FACP, FASCO, discusses the need to increase awareness regarding treating adolescents and young adults with colorectal cancer.

Dr. Mirhadi on Novel Radiation Technologies in NSCLC

February 20th 2020

Amin J. Mirhadi, MD, discusses novel radiation approaches that are being used in non–small cell lung cancer.

Dr. Mita on Emergence of Checkpoint Inhibitors SCLC

February 20th 2020

Alain C. Mita, MD, discusses the impact of checkpoint inhibitors on the small cell lung cancer treatment paradigm.

Dr. Chon on Challenges With Maintenance Therapy in Ovarian Cancer

February 20th 2020

Hye Sook Chon, MD, gynecologic oncologist, Moffitt Cancer Center, discusses challenges that are still faced in the maintenance setting in advanced ovarian cancer.

Dr. Penson on Biomarkers of Response to PARP Inhibitors in Ovarian Cancer

February 20th 2020

Richard T. Penson, MD, MRCP, associate professor, Harvard Medical School, and clinical director, Medical Gynecologic Oncology, Medicine, Massachusetts General Hospital, discusses prospective biomarkers that may predict response to PARP inhibitors in advanced ovarian cancer.

Dr. Hoffman on Primary Debulking Versus Neoadjuvant Chemotherapy in Ovarian Cancer

February 20th 2020

Mitchel Hoffman, MD, gynecologic oncologist, Moffitt Cancer Center, discusses eligibility criteria for primary debulking surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.

Dr. Husain on Liquid Biopsy Versus Tissue Biopsy in NSCLC

February 20th 2020

Hatim Husain, MD, discusses the utility of liquid biopsy versus tissue biopsy in non–small cell lung cancer.

Dr. Luke on Predictive Biomarkers in Metastatic Melanoma

February 20th 2020

Jason J. Luke, MD, FACP, discusses predictive biomarkers in metastatic melanoma.

Dr. Levy on Repeat Testing in NSCLC

February 20th 2020

Benjamin P. Levy, MD, discusses the importance of repeat testing in non–small cell lung cancer.

Dr. Pal on the Rationale for Adding Cabozantinib to Atezolizumab in Prostate Cancer

February 19th 2020

Sumanta K. Pal, MD, discusses the rationale for adding cabozantinib to atezolizumab in prostate cancer.

Dr. Pennell on Considerations for Immediate Treatment in Lung Cancer

February 19th 2020

Nathan A. Pennell, MD, PhD, discusses the considerations when choosing therapy for patients with lung cancer who need immediate therapy but have not received the results of their molecular testing.

Dr. Crafton on Considerations for Secondary Cytoreduction in Ovarian Cancer

February 19th 2020

Sarah Crafton, MD, discusses the personalized choice of undergoing secondary cytoreduction for patients with ovarian cancer.

Dr. Pasquini on Tisagenlecleucel in Real-World and Clinical Trial Settings in ALL and DLBCL

February 19th 2020

Marcelo Pasquini, MD, discusses the similarities between real-world experience with tisagenlecleucel and in the ELIANA and JULIET trials.

Dr. Fowler on Patient Eligibility for Cytoreductive Surgery in Ovarian Cancer

February 19th 2020

Jeffrey M. Fowler, MD, discusses patient eligibility for cytoreductive surgery in newly diagnosed ovarian cancer.

Dr. Freedland on a Real-World Analysis of Enzalutamide in mCRPC

February 19th 2020

Stephen J. Freedland, MD, discusses a real-world analysis of enzalutamide in metastatic castration-resistant prostate cancer.

Dr. Bakouny on the Role of Cytoreductive Nephrectomy in mRCC

February 19th 2020

Ziad Bakouny, MD, MSc, discusses the role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

The Potential Utility of CLR 131 in Multiple Myeloma

February 19th 2020

Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.

Dr. Cercek on the Impact of Tumor Sidedness on Frontline Treatment in mCRC

February 19th 2020

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the impact of tumor sidedness on frontline treatment decisions in metastatic colorectal cancer (mCRC).